The 25% price reduction for the TLD “will enable governments with limited resources to expand access to essential HIV services,” the Global Fund said in a statement.
ADVERTISING
The agency has been fighting since 2002 against HIV, tuberculosis and malaria, among others, through the joint purchase of medicines.
TLD is a single-tablet antiretroviral treatment that combines doses of tenofovir disoproxil fumarate, lamivudine and dolutegravir.
Since 2018, it has been recommended by the World Health Organization (WHO) as the preferred treatment for people with HIV, because it quickly eliminates the virus, has fewer side effects and is easy to administer.
ADVERTISING
“Countries hardest hit by HIV face significant budgetary obstacles, while millions of HIV-positive people lack access to quality treatment,” Global Fund Executive Director Peter Sands said in a statement.
“By reducing the price of the TLD, governments and other entities responsible for implementing grants from the Global Fund will be able to expand their treatment programs and invest even more in prevention, thus saving more lives, and reducing the number of new infections” , he explained.
Read also
* The text of this article was partially generated by artificial intelligence tools, state-of-the-art language models that assist in the preparation, review, translation and summarization of texts. Text entries were created by the Curto News and responses from AI tools were used to improve the final content.
It is important to highlight that AI tools are just tools, and the final responsibility for the published content lies with the Curto News. By using these tools responsibly and ethically, our objective is to expand communication possibilities and democratize access to quality information. 🤖
ADVERTISING
